Aclaris Therapeutics Stock Forecast
Aclaris Therapeutics stock price down 0.48% on Friday
(Updated on May 26, 2023)
The Aclaris Therapeutics stock price fell by -0.480% on the last day (Friday, 26th May 2023) from $8.33 to $8.29. It has now fallen 3 days in a row. During the last trading day the stock fluctuated 2.50% from a day low at $8.19 to a day high of $8.39. The price has been going up and down for this period, and there has been a 5.07% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -7 thousand shares and in total, 295 thousand shares were bought and sold for approximately $2.45 million.
Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.
The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -8.85% during the next 3 months and, with a 90% probability hold a price between $5.49 and $10.68 at the end of this 3-month period.
ACRS Signals & Forecast
There are mixed signals in the stock today. The Aclaris Therapeutics stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $8.33 and $8.70. A break-up above any of these levels will issue buy signals. Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements. A buy signal was issued from a pivot bottom point on Monday, March 06, 2023, and so far it has risen 17.26%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD).
Support, Risk & Stop-loss for Aclaris Therapeutics stock
Aclaris Therapeutics finds support from accumulated volume at $7.89 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.205 between high and low, or 2.50%. For the last week, the stock has had daily average volatility of 4.12%.
Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.
Trading Expectations (ACRS) For The Upcoming Trading Day Of Tuesday 30th
For the upcoming trading day on Tuesday, 30th we expect Aclaris Therapeutics to open at $8.29, and during the day (based on 14 day Average True Range), to move between $7.87 and $8.71, which gives a possible trading interval of +/-$0.416 (+/-5.02%) up or down from last closing price. If Aclaris Therapeutics takes out the full calculated possible swing range there will be an estimated 10.04% move between the lowest and the highest trading price during the day.
Since the stock is closer to the resistance from accumulated volume at $8.33 (0.48%) than the support at $7.89 (4.83%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.
Is Aclaris Therapeutics stock A Buy?
Aclaris Therapeutics holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Current score: -1.900 Open Broker Account
Sell Candidate UnchangedPredicted Opening Price for Aclaris Therapeutics of Tuesday, May 30, 2023
The predicted opening price is based on yesterday's movements between high, low, and closing price.
| Fair opening price May 30, 2023 | Current price |
|---|---|
| $8.29 | $8.29 (Overvalued) |
Remember To Visit Our YouTube Channel
Trading levels for ACRS
Fibonacci Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 8.49 | 2.45 % | |
| R2 | 8.42 | 1.51 % | ||
| R1 | 8.37 | 0.92 % | ||
| Current price: | 8.29 | |||
| Support | S1 | 8.21 | -0.96 % | |
| S2 | 8.16 | -1.55 % | ||
| S3 | 8.08 | -2.49 % |
Accumulated Volume Support & Resistance Levels
| Level | Price | |||
|---|---|---|---|---|
| Resistance | R3 | 8.95 | 7.96 % | |
| R2 | 8.40 | 1.33 % | ||
| R1 | 8.33 | 0.483 % | ||
| Current price | 8.29 | |||
| Support | S1 | 7.89 | -4.83% | |
| S2 | 7.41 | -10.62% | ||
| S3 | 7.07 | -14.72% |
FAQ
Click here for our free guide on how to buy Aclaris Therapeutics Stock.
About Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of... ACRS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
